We have collected information about Formulations For Delivery Of Therapeutic Proteins for you. Follow the links to find out details on Formulations For Delivery Of Therapeutic Proteins.
https://link.springer.com/10.1007/s10529-008-9834-y
Sep 11, 2008 · Advances in biotechnology have now created a capacity to produce therapeutically active proteins on a commercial scale, opening the potential for their application in an array of disease conditions. The process of translation of the variety of different therapeutic proteins into the medicines used in clinics is now occurring. To assist in this translation, new formulations to deliver proteins ...Author: Snjezana Stolnik, Kevin Shakesheff
https://www.researchgate.net/publication/23250535_Formulations_for_delivery_of_therapeutic_proteins
Formulations for delivery of therapeutic proteins Article · Literature Review in Biotechnology Letters 31(1):1-11 · October 2008 with 18 Reads How we measure 'reads'
https://onlinelibrary.wiley.com/doi/pdf/10.1002/9780470571224.pse313
Mar 15, 2010 · The protein therapeutics have unique handling and development requirements relative to the small organic molecule‐based drugs and pose exclusive challenges for the formulation scientist. The formulation and delivery issues of therapeutic proteins can contribute to difficulties in pharmaceutical development such as stability, immune toxicity ...Author: Sathy V. Balu‐Iyer, Sathy V. Balu‐Iyer, Razvan D. Miclea, Vivek S. Purohit
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857543/
Lipid drug delivery is another area that has shown great promise for use with therapeutic proteins. 116 – 118 As a whole, lipid delivery encompasses liposomes, solid lipid nanoparticles, oily suspensions, submicron lipid emulsions, lipid implants, lipid microbubbles, inverse lipid micelles, cochliar liposomes, and lipid microtubules, and lipid microcylinders (Figure 3A). 119 The most …Author: Dipak S. Pisal, Matthew P. Kosloski, Sathy V. Balu-Iyer
https://www.flandershealth.us/therapeutic-proteins/formulation-development-of-proteins.html
Adsorption to hydrophobic glass surfaces has been a known therapeutic protein formulation issue for many years. Early reports detail the prevention of insulin adsorption to glass surfaces with the addition of gelatin (56). As mentioned already, adding surface-active agents (e.g.,...
https://www.deepdyve.com/lp/springer-journals/formulations-for-delivery-of-therapeutic-proteins-903wHnrEJA
Sep 11, 2008 · Formulations for delivery of therapeutic proteins Formulations for delivery of therapeutic proteins Stolnik, Snjezana; Shakesheff, Kevin 2008-09-11 00:00:00 Advances in biotechnology have now created a capacity to produce therapeutically active proteins on a commercial scale, opening the potential for their application in an array of disease conditions.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944732/
Sep 11, 2019 · Consequently, non-invasive drug delivery systems for therapeutic proteins have gained great attention in the research and development of biomedicines. Therefore, this review covers the various formulation approaches to optimizing the delivery properties of protein drugs with an emphasis on improving bioavailability and patient compliance.Author: Rajiv Bajracharya, Jae Geun Song, Seung Yun Back, Hyo-Kyung Han
https://www.amazon.com/Protein-Formulation-Delivery-Pharmaceutical-Sciences/dp/0849379490
This title is intended to assist pharmaceutical scientists in the development of stable protein formulations during the early stages of the product development process, providing a comprehensive review of mechanisms and causes of protein instability in formulation development, coverage of accelerated stability testing methods and relevant analytical methods, and an overview of the drug substance manufacturing …Author: Eugene J. McNally
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/protein-formulation
Opalescence in a therapeutic protein formulation may be determined per the European Pharmacopoeia 5.0, Section 2.2. Physical and Physiochemical Methods and Section 2.2.1 Clarity and Degree of Opalescence of Liquids (European Pharmacopoeia, 2011). Section 2.2.1 describes one way of determining opalescence using a visual method or with an instrument.
https://www.sciencedirect.com/science/article/pii/S0022354918300078
Erythropoietin is an often cited example of a therapeutic protein with better efficacy dosed SC rather than IV because of a prolongation of systemic exposure when given this route that allows for a reduction in dosing.5, 6 This phenomenon can be described by the concept of flip-flop kinetics, where the absorption rate is the limiting step for drug clearance. 7 Flip-flop kinetics have also been reported …Author: Michael R. Turner, Sathy V. Balu-Iyer
Searching for Formulations For Delivery Of Therapeutic Proteins?
You can just click the links above. The data is collected for you.
